Vermillion, Inc. is engaged in the discovery, development and commercialization of diagnostic tests that helps physicians diagnose, treat and improve outcomes for patients. The Company's tests are intended to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in the selection of therapy. The Company combines multiple biomarkers into a single, reportable index score. The Company concentrates its development of diagnostic tests in the fields of oncology, cardiology and women's health, with the initial focuses on ovarian cancer.The Company's product, OVA1, addresses a clear unmet clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor.In addition to OVA1, the Company has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease.
Suite 100, 12117 Bee Caves Rd.
AUSTIN, TX, United States 78738
|Chairman of the Board||Bruce Huebner|
|President, Chief Executive Officer||Thomas McLain|
|Chief Accounting Officer||Eric Schoen|
|Vice President - Sales and Marketing||William Creech|
|Vice President - Research & Development, Chief Scientific Officer||Donald Munroe|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||15.2M||Book Value||$0.31|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||22.4|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-411.46%|
*GAAP = prior to non-GAAP analyst adjusted earnings.